Immunalysis Methamphetamine Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators

K153693 · Immunalysis Corporation · LAF · Mar 18, 2016 · Clinical Toxicology

Device Facts

• Record ID: K153693
• Device Name: Immunalysis Methamphetamine Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators
• Applicant: Immunalysis Corporation
• Product Code: LAF · Clinical Toxicology
• Decision Date: Mar 18, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3610
• Device Class: Class 2

Indications for Use

The Immunalysis Methamphetamine Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with dual cutoffs of 500ng/mL and 1000ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Methamphetamine in human urine with automated clinical chemistry analyzers. This assay is calibrated against Methamphetamine. This in-vitro diagnostic device is for prescription use only. The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas Chromatography/ Mass Spectrometry (GC-MS) or permitting laboratories to establish quality control procedures. The Immunalysis Methamphetamine Urine Enzyme Immunoassay Kit provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC-MS or Liquid Chromatography / Mass Spectrometry (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. The Immunalysis Multi-Drug Calibrators are intended for in vitro diagnostic use for the calibration of assays for the analytes currently listed in the package insert: Benzoylecgonine, Methamphetamine, Morphine, PCP and Oxazepam. The calibrators are designed for prescription use with immunoassays.

Device Story

The Immunalysis Methamphetamine Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay used in clinical laboratories to detect methamphetamine in human urine. The device utilizes automated clinical chemistry analyzers to process urine samples. The assay reagents include monoclonal antibodies to methamphetamine, glucose-6-phosphate, NAD, and a methamphetamine derivative labeled with glucose-6-phosphate dehydrogenase. The principle of operation is based on competitive binding; the presence of methamphetamine in the sample competes with the enzyme-labeled drug for antibody binding sites, resulting in a measurable change in enzyme activity. The device provides qualitative and semi-quantitative results, which are used by clinicians to identify potential drug use and determine the need for confirmatory testing via GC-MS or LC/MS. The Immunalysis Multi-Drug Calibrators are used to calibrate the assay. The device aids in clinical decision-making by providing preliminary screening results, allowing for efficient laboratory workflows and timely patient assessment.

Clinical Evidence

Performance was evaluated using 80 clinical urine samples compared against LC-MS/MS. Qualitative and semi-quantitative modes were tested at 500ng/mL and 1000ng/mL cutoffs. Results showed high agreement (98-100%) with LC-MS/MS confirmation. Precision, specificity, and interference studies (including pH, specific gravity, and common drugs/endogenous compounds) were conducted on a Beckman Coulter AU 400e analyzer, confirming the assay is robust and unaffected by potential interferents.

Technological Characteristics

Homogeneous enzyme immunoassay; reagents include monoclonal antibody to Methamphetamine, G6P, NAD, and Methamphetamine-labeled G6PDH. Liquid, ready-to-use format. Energy source: spectrophotometric measurement at 340nm. Storage: 2–8°C. Compatible with automated clinical chemistry analyzers capable of precise temperature control, pipetting, and timing.

Indications for Use

Indicated for the qualitative and semi-quantitative analysis of Methamphetamine in human urine in laboratory settings using automated clinical chemistry analyzers. Intended for prescription use only. Provides preliminary analytical results requiring confirmation by GC-MS or LC/MS.

Regulatory Classification

Identification

A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.

Special Controls

*Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• Microgenics, Inc. DRI® Methamphetamines Assay (k093114)
• Lin-Zhi International Multi-Analyte Urine Drugs of Abuse Calibrators (k051088)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM ASSAY ONLY TEMPLATE

A. 510(k) Number:
k153693

B. Purpose for Submission:
New device

C. Measurand:
Methamphetamine

D. Type of Test:
Homogenous enzyme immunoassay

E. Applicant:
Immunalysis Corporation

F. Proprietary and Established Names:
Immunalysis Methamphetamine Urine Enzyme Immunoassay
Immunalysis Multi-Drug Calibrators

G. Regulatory Information:
| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| LAF | Class II | 21 CFR 862.3610, Methamphetamine test system | Toxicology (91) |
| DLJ | Class II | 21 CFR 862.3200, Clinical toxicology calibrator | Toxicology (91) |

H. Intended Use:
1. Intended use(s):
Refer to Indications for Use below.

{1}

2. Indication(s) for use:

The Immunalysis Methamphetamine Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with dual cutoffs of 500ng/mL and 1000ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Methamphetamine in human urine with automated clinical chemistry analyzers. This assay is calibrated against Methamphetamine. This in-vitro diagnostic device is for prescription use only.

The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas Chromatography/ Mass Spectrometry (GC-MS) or permitting laboratories to establish quality control procedures.

The Immunalysis Methamphetamine Urine Enzyme Immunoassay Kit provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC-MS or Liquid Chromatography / Mass Spectrometry (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

The Immunalysis Multi-Drug Calibrators are intended for in vitro diagnostic use for the calibration of assays for the analytes currently listed in the package insert: Benzoylecgonine, Methamphetamine, Morphine, PCP and Oxazepam. The calibrators are designed for prescription use with immunoassays.

3. Special conditions for use statement(s):

For prescription use only.

For in vitro diagnostic use only.

4. Special instrument requirements:

The Beckman Coulter AU400e Chemistry Analyzer was used to generate the performance data in this submission. Instruments must be capable of maintaining a constant reaction temperature, pipetting samples and reagents, mixing reagents, timing reactions and measuring enzyme rates precisely.

I. Device Description:

The assay consists of antibody/ substrate reagent and enzyme conjugate reagent. The antibody/ substrate reagent includes monoclonal antibodies to Methamphetamine, glucose-6-phosphate (G6P) and nicotinamide adenine dinucleotide (NAD) in Tris buffer with Sodium Azide as a preservative. The enzyme conjugate reagent includes Methamphetamine derivative labeled with glucose-6-phosphate dehydrogenase (G6PDH) in Tris buffer with Sodium Azide

2

{2}

as a preservative.

All of the Immunalysis Multi-Drug Calibrators are liquid and ready to use. Each contains a known concentration of a specific drug analyte as a mixture. The negative calibrator is a processed, drug-free synthetic urine matrix with sodium azide as a preservative. The Level 1, 2, 3 and 4 calibrators are prepared by spiking known concentrations of drug analyte into the negative calibrator matrix. These five calibrators (negative, Level 1, 2, 3 and 4) are sold as individual bottles. The concentration of drug analyte in the corresponding calibrators is summarized as follows:

| Analyte | Multi-Drug Calibrators | | | |
| --- | --- | --- | --- | --- |
| | Level 1 | Level 2 | Level 3 | Level 4 |
| Benzoylecgonine | 150 ng/mL | 300 ng/mL | 500 ng/mL | 1000 ng/mL |
| Methamphetamine | 500 ng/mL | 1000 ng/mL | 1500 ng/mL | 2000 ng/mL |
| Morphine | 100 ng/mL | 300 ng/mL | 500 ng/mL | 1000 ng/mL |
| PCP | 12.5 ng/mL | 25 ng/mL | 50 ng/mL | 100 ng/mL |
| Oxazepam | 100 ng/mL | 200 ng/mL | 500 ng/mL | 1000 ng/mL |

## J. Substantial Equivalence Information:

1. Predicate device name(s):

Microgenics, Inc. DRI® Methamphetamines Assay

Lin-Zhi International Multi-Analyte Urine Drugs of Abuse Calibrators

2. Predicate 510(k) number(s):

k093114

k051088

3. Comparison with predicate:

| Similarities - Reagent | | |
| --- | --- | --- |
| Item | Predicate Device Microgenics, Inc. DRI Methamphetamines Assay k093114 | Candidate Device Immunalysis Methamphetamine Urine Enzyme Immunoassay |
| Intended Use | For the qualitative and semi-quantitative determination of Methamphetamine in human urine | Same |
| Measured Analytes | Methamphetamine and | Methamphetamine |

{3}

| Similarities - Reagent | | |
| --- | --- | --- |
| | Amphetamine | |
| Test Matrix | Urine | Same |
| Item | Predicate Device Microgenics, Inc. DRI Methamphetamines Assay k093114 | Candidate Device Immunalysis Methamphetamine Urine Enzyme Immunoassay |
| Cutoff Levels | 500 ng/mL and 1000 ng/mL of Methamphetamine and Amphetamine | 500 ng/mL and 1000 ng/mL of Methamphetamine |
| Methodology | Homogeneous Enzyme Immunoassay | Same |
| Materials | Liquid Ready-to-Use Two Reagent Assay (R1 and R2) | Antibody/Substrate Reagents and Enzyme Labeled Conjugate |
| Storage | 2 – 8°C until expiration date | Same |
| Differences - Reagent | | |
| --- | --- | --- |
| Item | Predicate Device Microgenics, Inc. DRI Methamphetamines Assay k093114 | Candidate Device Immunalysis Methamphetamine Urine Enzyme Immunoassay |
| Antibody | Monoclonal antibodies to Methamphetamine and/or Amphetamine | Monoclonal antibody to Methamphetamine |
| Similarities - Calibrators | | |
| --- | --- | --- |
| Item | Predicate Device Lin-Zhi International Multi-Analyte Urine Drugs of Abuse Calibrators k051088 | Candidate Device Immunalysis Multi-Drug Calibrators |
| Matrix | Urine | Same |
| Calibrator Levels | 5 Levels | Same |
| Storage | 2 – 8°C until expiration date | Same |

{4}

| Differences - Calibrators | | |
| --- | --- | --- |
| Item | Predicate Device Lin-Zhi International Multi-Analyte Urine Drugs of Abuse Calibrators k051088 | Candidate Device Immunalysis Multi-Drug Calibrators |
| Analytes | benzoylecgonine, d-methamphetamine, methadone, morphine, oxazepam, secobarbital, phencyclidine, propoxyphene | benzoylecgonine, methamphetamine, morphine, PCP |

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP07-A2: Interference Testing in Clinical Chemistry: Approved Guideline - Second Edition

# L. Test Principle:

The assay is based on the competition of Methamphetamine labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free drug in the urine sample for a fixed amount of antibody binding sites. In the absence of the free drug in the sample, the antibody binds the drug enzyme conjugate and enzyme activity is inhibited. This creates a dose response relationship between drug concentration in the urine sample and enzyme activity. The enzyme G6PDH activity is determined at $340\mathrm{nm}$ spectrophotometrically by the conversion of NAD to NADH.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

The sponsor performed precision studies in-house following the guidelines provided in CLSI EP5-A2. The study was performed using drug free urine samples spiked with methamphetamine and analyzed on a Beckman Coulter / Olympus AU400e Chemistry Analyzer. Samples were measured in duplicate in two runs per day for 20 days $(n = 80)$ . The data are summarized in the following tables:

{5}

Qualitative analysis (500 ng/mL cutoff)

| Concentration (ng/mL) | % of cutoff | Result |
| --- | --- | --- |
| 0 | -100 | 80 Neg / 0 Pos |
| 125 | -75 | 80 Neg / 0 Pos |
| 250 | -50 | 80 Neg / 0 Pos |
| 375 | -25 | 80 Neg / 0 Pos |
| 500 | Cutoff | 41 Neg / 39 Pos |
| 625 | +25 | 80 Pos / 0 Neg |
| 750 | +50 | 80 Pos / 0 Neg |
| 875 | +75 | 80 Pos / 0 Neg |
| 1000 | +100 | 80 Pos / 0 Neg |

Qualitative analysis (1000 ng/mL cutoff)

| Concentration | % of cutoff | Result |
| --- | --- | --- |
| 0 | -100 | 80 Neg / 0 Pos |
| 250 | -75 | 80 Neg / 0 Pos |
| 500 | -50 | 80 Neg / 0 Pos |
| 750 | -25 | 80 Neg / 0 Pos |
| 1000 | Cutoff | 44 Neg / 36 Pos |
| 1250 | +25 | 80 Pos / 0 Neg |
| 1500 | +50 | 80 Pos / 0 Neg |
| 1750 | +75 | 80 Pos / 0 Neg |
| 2000 | +100 | 80 Pos / 0 Neg |

Semi-quantitative analysis (500 ng/mL cutoff)

| Concentration | % of cutoff | Result |
| --- | --- | --- |
| 0 | -100 | 80 Neg / 0 Pos |
| 125 | -75 | 80 Neg / 0 Pos |
| 250 | -50 | 80 Neg / 0 Pos |
| 375 | -25 | 80 Neg / 0 Pos |
| 500 | Cutoff | 35 Neg / 45 Pos |
| 625 | +25 | 80 Pos / 0 Neg |
| 750 | +50 | 80 Pos / 0 Neg |
| 875 | +75 | 80 Pos / 0 Neg |
| 1000 | +100 | 80 Pos / 0 Neg |

Semi-quantitative analysis (1000 ng/mL cutoff)

| Concentration | % of cutoff | Result |
| --- | --- | --- |
| 0 | -100 | 80 Neg / 0 Pos |
| 250 | -75 | 80 Neg / 0 Pos |
| 500 | -50 | 80 Neg / 0 Pos |
| 750 | -25 | 80 Neg / 0 Pos |
| 1000 | Cutoff | 37 Neg / 43 Pos |
| 1250 | +25 | 80 Pos / 0 Neg |
| 1500 | +50 | 80 Pos / 0 Neg |
| 1750 | +75 | 80 Pos / 0 Neg |
| 2000 | +100 | 80 Pos / 0 Neg |

{6}

b. Linearity/assay reportable range:

A drug free urine pool was spiked with a high concentration of Methamphetamine (at a level above the highest calibrator) and was used as the high value specimen. Additional pools were made by serially diluting the high value specimen with drug free urine in increments of about 10%. Aliquots from each pool were analyzed in triplicate in the semi-quantitative mode.. For each known concentration, drug recovery was calculated using the mean concentration of the replicates. The results of the study are summarized below:

| Expected Concentration (ng/mL) | Mean Concentration (ng/mL) | Recovery (%) |
| --- | --- | --- |
| 200 | 272.7 | 136.4 |
| 400 | 436.8 | 109.2 |
| 600 | 674.6 | 112.4 |
| 800 | 830.0 | 103.8 |
| 1000 | 1107.6 | 110.8 |
| 1200 | 1247.0 | 103.9 |
| 1400 | 1481.2 | 105.8 |
| 1600 | 1711.5 | 107.0 |
| 1800 | 1917.4 | 106.5 |
| 2000 | 2080.7 | 104.0 |
| 2200 | 2226.4 | 101.2 |

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The analytes in the calibrators have been traced to a commercially available standard solution. The standard is certified material with the concentration verified by GC-MS or LC/MS-MS. This standard is diluted with calibrator buffer to make the calibrators in the desired concentrations. The concentrations are confirmed by Gas Chromatography and Mass Spectrometry Analysis (GC-MS) and/or Liquid Chromatography/ Tandem Mass Spectrometry (LC/MS-MS).

Stability protocols and acceptance criteria for the calibrators were reviewed and found to be acceptable. The sponsor claims that when stored at 2 – 8°C calibrators and controls are stable for one year. The sponsor claims that once opened, the calibrators and controls are stable for 60 days when stored at 2 – 8°C.

The Negative Calibrator is a processed, drug free urine matrix. The standard is compared to a reference negative standard to ensure that it is free of analyte. Value is assigned when the test is within the acceptable range.

{7}

Values are assigned to the controls and calibrators once the GC/MS or LC/MS/MS results are within the acceptable ranges. The negative standard is prepared with BSA Buffer. The standard is compared to a reference negative standard to ensure that it is free of analyte. The value is assigned when the test is within the acceptable range.

d. Detection limit:

Not applicable.

e. Analytical specificity:

Potential interference from non-structurally related compounds and endogenous compounds was evaluated in both the qualitative and semi-quantitative modes by following CLSI EP 7-A2: Interference Testing in Clinical Chemistry. Potential interferents were spiked into drug free urine containing Methamphetamine at ± 25% of the cutoff (375 ng/mL and 625 ng/mL for the 500 ng/mL cutoff or 750 ng/mL and 1,250 ng/mL for the 1,000 ng/mL cutoff). The following compounds at 100,000 ng/mL were found not to interfere with the assay at either cutoff in qualitative or semi-quantitative mode.

| 4-Bromo-2,5,Dimethoxy phenethylamine | Ethylmorphine | Norbuprenorphine |
| --- | --- | --- |
| 6-Acetylmorphine | Fentanyl | Norcodeine |
| 7-Aminoclonazepam | Flunitrazepam | Nordiazepam |
| Alprazolam | Fluoxetine | Normorphine |
| Amitriptyline | Flurazepam | Norpropoxyphene |
| Amobarbital | Heroin | Nortriptyline |
| Benzylpiperazine | Hexobarbital | Oxazepam |
| Bromazepam | Hydrocodone | Oxycodone |
| Buprenorphine | Hydromorphone | Oxymorphone |
| Bupropion | 11-hydroxy-Δ-9-THC | Phencyclidine |
| Butabarbital | Ibuprofen | Pentazocine |
| Carbamazepine | Imipramine | Pentobarbital |
| Chlordiazepoxide | Ketamine | Phenobarbital |
| Chlorpromazine | Levorphanol Tartrate | Phentermine |
| cis-Tramadol | Lidocaine | Phenytoin |
| Clobazam | Lorazepam | Prazepam |
| Clomipramine | LSD | Propranolol |
| Clonazepam | Maprotiline | Protriptyline |
| Cocaine | Meperidine | Ranitidine |
| Codeine | Meprobamate | Ritalinic Acid |
| Cyclobenzaprine | Methadone | Secobarbital |
| N-Desmethyltapentadol | Methaquolone | Sufentanil Citrate |
| Delta-9-THC | Methylphenidate | Temazepam |

{8}

9

| Desipramine | Morphine | 11-nor-9 carboxy THC |
| --- | --- | --- |
| Dextromethorphan | Morphine-3β-glucuronide | Thioridazine |
| Diazepam | Morphine-6β-glucuronide | Triazolam |
| Dihydrocodeine | Nalorphine | Trifluoromethyl phenyl-piperazine |
| Doxepin | Naloxone | Trimipramine |
| EDDP | Naltrexone | Venlafaxine |
| Ethyl β-D-glucuronide | Nitrazepam | |

In addition, Acetaminophen, Acetylsalicylic Acid, Benzoylecgonine, and Caffeine were found not to interfere at a concentration of 500,000 ng/mL.

The following endogenous substances at the concentrations listed below did not interfere with the assay at either cutoff in qualitative or semi-quantitative mode:

| Compound | Concentration Tested |
| --- | --- |
| Acetone | 1.0 g/dL |
| Ascorbic Acid | 1.5 g/dL |
| Bilirubin | 0.002 g/dL |
| Creatinine | 0.5 g/dL |
| Ethanol | 1.0 g/dL |
| Galactose | 0.01 g / dL |
| γ-Globulin | 0.5 g/dL |
| Glucose | 2.0 g/dL |
| Hemoglobin | 0.150 g/dL |
| Human Serum Albumin | 0.5 g/dL |
| Oxalic Acid | 0.1 g/dL |
| Riboflavin | 0.0075 g/dL |
| Sodium Azide | 1% w/v |
| Sodium Chloride | 6.0 g/dL |
| Sodium Fluoride | 1% w/v |
| Urea | 6.0 g/dL |

Boric acid at a concentration of 1% w/v was found to cause false negative results at +25% and +50% of the cutoff for both qualitative and semi-quantitative modes. The labeling recommends that Boric Acid not be used as a preservative for urine samples.

Effect of pH: The sponsor evaluated the effect of pH on the test results using both qualitative and semi-quantitative modes. Drug free urine containing Methamphetamine at ±25% of the cutoff (375 ng/mL and 625 ng/mL for the 500 ng/mL cutoff and 750 ng/mL and 1250 ng/mL for the 1000 ng/mL cutoff) were pH adjusted using hydrochloric acid or sodium hydroxide. pH values of 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0 did not interfere with the test result at either cutoff in qualitative or semi-quantitative mode.

{9}

Effect of specific gravity: The sponsor evaluated the effect of specific gravity on the test results using both qualitative and semi-quantitative modes. Drug free urine containing Methamphetamine at $\pm 25\%$ of the cutoff (375 ng/mL and 625 ng/mL for the 500 ng/mL cutoff and 750 ng/mL and 1250 ng/mL for the 1000 ng/mL cutoff) were adjusted using salt or albumin. Specific Gravity values of 1.000, 1.002, 1.005, 1.010, 1.015, 1.020, 1.025 and 1.030 did not interfere with the test result at either cutoff in qualitative or semi-quantitative mode.

Cross reactivity from structurally related compounds was evaluated in the qualitative and semi-quantitative modes by spiking into drug-free urine. Each potential cross-reacting compound was spiked and evaluated independently, and each spiked sample was tested in singlicate. No differences were observed between the qualitative and semi-quantitative modes. The compounds tested and the concentration approximately equivalent to the 500 and $1000\mathrm{ng / mL}$ cutoffs are listed below:

| 500 ng/mL cutoff | | |
| --- | --- | --- |
| Compound | Concentration Tested (ng/mL) | Cross-Reactivity (%) |
| (+) Methamphetamine | 500 | 100.00 |
| (-) Methamphetamine | 90,000 | 0.56 |
| (+) Amphetamine | 20,000 | 2.50 |
| (-) Amphetamine | 900,000 | 0.06 |
| Methylenedioxyamphetamine (MDA) | 18,000 | 2.78 |
| Methoxyamphetamine (PMA) | 15,000 | 3.33 |
| Methylenedioxymethamphetamine (MDMA) | 800 | 62.50 |
| MDEA | 3,000 | 16.67 |
| Fenfluramine | 7,000 | 7.14 |
| (+) Pseudoephedrine | 75,000 | 0.67 |
| (-) Pseudoephedrine | 300,000 | 0.17 |
| (-) Ephedrine | 65,000 | 0.77 |
| (+) Ephedrine | 1,000,000 | <0.05 |
| Phentermine | 500,000 | 0.10 |
| Tyramine | 850,000 | 0.06 |
| Phenylephrine | 800,000 | 0.06 |
| Diphenhydramine | 1,000,000 | <0.050 |
| Phenylpropanolamine | 1,000,000 | < 0.0005 |

{10}

| 1000 ng/mL cutoff | | |
| --- | --- | --- |
| Compound | Concentration Tested (ng/mL) | Cross-Reactivity (%) |
| (+) Methamphetamine | 1,000 | 100.00 |
| (-) Methamphetamine | 200,000 | 0.44 |
| (+) Amphetamine | 60,000 | 2.50 |
| (-) Amphetamine | 1,000,000 | <0.10 |
| Methylenedioxyamphetamine (MDA) | 40,000 | 2.50 |
| Methoxyamphetamine (PMA) | 40,000 | 3.33 |
| Methylenedioxymethamphetamine (MDMA) | 1,000 | 71.43 |
| MDEA | 5,000 | 14.29 |
| Fenfluramine | 10,000 | 6.06 |
| (+) Pseudoephedrine | 200,000 | 0.67 |
| (-) Pseudoephedrine | 1,000,000 | 0.13 |
| (-) Ephedrine | 200,000 | 0.57 |
| (+) Ephedrine | 1,000,000 | <0.10 |
| Phentermine | 1,000,000 | <0.10 |
| Tyramine | 1,000,000 | <0.10 |
| Phenylephrine | 1,000,000 | <0.10 |
| Diphenhydramine | 1,000,000 | <0.10 |
| Phenylpropanolamine | 1,000,000 | <0.10 |

f. Assay cut-off:

Analytical performance of the device around the claimed cutoff is described in the precision section M.1.a. above.

2. Comparison studies:

a. Method comparison with predicate device:

The method comparison study was performed in-house using unaltered, clinical urine samples obtained from clinical testing laboratories. A total of 80 samples were analyzed using both the $500\mathrm{ng / mL}$ and $1000\mathrm{ng / mL}$ cutoffs. Each sample was run in singlicate on a Beckman Coulter AU400e Chemistry Analyzer and the result was compared to that obtained by liquid chromatography/mass spectroscopy (LC/MS). The results of the assay performance compared to LC/MS are summarized below:

{11}

500 ng/mL cutoff (n = 80)

| Candidate Device Result | Methamphetamine Concentration by LC/MS (ng/mL) | | | |
| --- | --- | --- | --- | --- |
| | < 250 | 250 – 499 | 500 – 750 | > 750 |
| Qualitative / POS | 0 | 0 | 4 | 36 |
| Qualitative / NEG | 36 | 4 | 0 | 0 |
| Semi-quant / POS | 0 | 1* | 4 | 36 |
| Semi-quant / NEG | 36 | 3 | 0 | 0 |

Qualitative agreement among positives = 40 / 40 (100%)
Qualitative agreement among negatives = 40 / 40 (100%)
Semi-quant agreement among positives = 40 / 40 (100%)
Semi-quant agreement among negatives = 39 / 40 (98%)

*Discordant sample – 500 ng/mL cutoff

| Candidate Device Result | | | | LC/MS result (ng/mL) |
| --- | --- | --- | --- | --- |
| Sample ID | Qualitative result | Semi-quantitative | | |
| | | Conc (ng/mL) | Result | |
| 358433ZA | POS | 544.9 | POS | 494 |

1000 ng/mL cutoff (n = 80)

| Candidate Device Result | Methamphetamine Concentration by LC/MS (ng/mL) | | | |
| --- | --- | --- | --- | --- |
| | < 500 | 500 – 999 | 1000 – 1500 | > 1500 |
| Qualitative / POS | 0 | 0 | 16 | 24 |
| Qualitative / NEG | 36 | 4 | 0 | 0 |
| Semi-quant / POS | 0 | 0 | 3 | 36 |
| Semi-quant / NEG | 36 | 4 | 1* | 0 |

Qualitative agreement among positives = 40 / 40 (100%)
Qualitative agreement among negatives = 40 / 40 (100%)
Semi-quant agreement among positives = 39 / 40 (98%)
Semi-quant agreement among negatives = 40 / 40 (100%)

*Discordant sample – 1000 ng/mL cutoff

| Candidate Device Result | | | | LC/MS result (ng/mL) |
| --- | --- | --- | --- | --- |
| Sample ID | Qualitative result | Semi-quantitative | | |
| | | Conc (ng/mL) | Result | |
| 358429ZA | POS | 998.5 | NEG | 1017 |

b. Matrix comparison:

Not applicable. This device is intended to be used with urine samples only.

3. Clinical studies:

{12}

a. Clinical Sensitivity:
Not applicable.

b. Clinical specificity:
Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.

4. Clinical cut-off:
Not applicable.

5. Expected values/Reference range:
Not applicable.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

13